Biodexa Pharmaceuticals Files 6-K Report
Ticker: BDRX · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
Related Tickers: BDRX
TL;DR
Biodexa Pharma (BDRX) filed a 6-K, standard reporting, nothing major to see here.
AI Summary
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on September 16, 2024. The company, incorporated in X0 with its principal executive office in Cardiff, United Kingdom, is a pharmaceutical preparations company. This filing is for the month of September 2024 and is incorporated by reference into their Form S-8 and Form F-3 registration statements.
Why It Matters
This filing indicates ongoing reporting requirements for Biodexa Pharmaceuticals PLC, ensuring transparency for investors regarding their corporate activities and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial or operational information.
Key Numbers
- 001-37652 — Commission File Number (Identifies the company's filing with the SEC.)
- 333-209365 — Form S-8 File Number (Registration statement for employee stock plans.)
- 333-267932 — Form F-3 File Number (Registration statement for offerings.)
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Registrant
- Midatech Pharma Plc (company) — Former company name
- 001-37652 (dollar_amount) — Commission File Number
- 333-209365 (dollar_amount) — Form S-8 File Number
- 333-267932 (dollar_amount) — Form F-3 File Number
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, filed for the month of September 2024.
What is the company's former name?
The company's former name was Midatech Pharma Plc, with a date of name change on June 2, 2015.
Where is Biodexa Pharmaceuticals PLC located?
The company's principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Under which SEC registration statements is this filing incorporated by reference?
This filing is incorporated by reference into the company's registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-267932).
What is the Standard Industrial Classification code for Biodexa Pharmaceuticals PLC?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 16.4 · Accepted 2024-09-16 08:40:05
Filing Documents
- f6k_091624.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-005198.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: September 16, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer